蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 6512|回复: 22
收起左侧

[欧盟药事] 英国MHRA发布GxP数据可靠性指南 2018年3月9日

  [复制链接]
药生
发表于 2018-3-10 09:24:38 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
2018年3月9日, 英国MHRA发布‘GXP’ 数据可靠性指和定义 (GxP Data Integrity Guidance and Definitions)

GxP 包括GCP, GDP, GLP, GMP和GPvP。MHRA在咨询过程中,GxP检查组收到来自行业,贸易和专业团体的超过1300条意见。本指南旨在通过教育促进合规性,同时明确MHRA在数据可靠性方面的立场以及达到合规性的最低期望。

MHRA_GxP.jpg

MHRA_GxP Data Iintegrity Guide 2018.pdf

445.34 KB, 下载次数: 436, 下载积分: 金币 -1

回复

使用道具 举报

药徒
发表于 2018-3-10 10:12:22 | 显示全部楼层
沙发,谢谢楼主分享
回复

使用道具 举报

药生
发表于 2018-3-10 10:12:56 | 显示全部楼层
回复

使用道具 举报

大师
发表于 2018-3-10 10:36:19 | 显示全部楼层
有中文版吗
回复

使用道具 举报

药徒
发表于 2018-3-10 10:48:49 | 显示全部楼层
回复

使用道具 举报

药士
发表于 2018-3-10 11:07:21 | 显示全部楼层
回复

使用道具 举报

药徒
发表于 2018-3-10 11:35:05 | 显示全部楼层
下载了,谢谢
回复

使用道具 举报

药士
发表于 2018-3-10 13:16:12 | 显示全部楼层

这么新的,哪有中文版的啊
回复

使用道具 举报

药士
发表于 2018-3-14 08:25:03 | 显示全部楼层
1300建议哪里能查询??与以前的征求意见稿有什么差异??具体的明细是否有?

点评

这是2015版本和2018版本(revison 1)之间的比较,具体的修订内容标示在(黄色加亮部分):https://vertassets.blob.core.windows.net/download/a88309a4/a88309a4-c5a9-4876-9f3e-9d6a85b5d629/marked_up__mhra_gxp_  详情 回复 发表于 2018-3-24 08:55
回复

使用道具 举报

药徒
发表于 2018-3-14 08:28:39 | 显示全部楼层
好东西 下了另外一个中英文版!

点评

问下中英文版本下载地址方便给吗  详情 回复 发表于 2018-9-2 10:42
回复

使用道具 举报

发表于 2018-3-15 10:21:21 | 显示全部楼层
谢谢分享!     
回复

使用道具 举报

药士
发表于 2018-3-24 08:55:34 | 显示全部楼层
beiwei5du 发表于 2018-3-14 08:25
1300建议哪里能查询??与以前的征求意见稿有什么差异??具体的明细是否有?

这是2015版本和2018版本(revison 1)之间的比较,具体的修订内容标示在(黄色加亮部分):https://vertassets.blob.core.windows.net/download/a88309a4/a88309a4-c5a9-4876-9f3e-9d6a85b5d629/marked_up__mhra_gxp_data_integrity_guide_rev_1_1_2018.pdf

What's New In MHRA's Revised Data Integrity Guidance — A Detailed Analysis

https://www.pharmaceuticalonline.com/doc/what-s-new-in-mhra-s-revised-data-integrity-guidance-a-detailed-analysis-0001


Nature Of Change
Change Details
Principles, Criticality, Risk, And System Design
Deletion
Figure 1 in the 2015 version, showing the spectrum of simple to complex computerized systems, has been removed. The text in section 4.3 of the 2018 version provides a narrative version of the 2015 Figure 1. The 2016 draft guidance included the figure; it was removed as an outcome of the consultation process.
Addition
The scope of the 2015 guidance was limited to GMP; the scope of the 2018 version includes GCP, GLP, and GMP for pharmaceuticals and excludes consideration of devices. Reference is made to the introduction section of the guidance. The introduction section is largely new in this revision.
Addition
The Principles of Data Integrity section introduces the acronym DIRA (data integrity risk assessment). Many of the 10 principles consolidated in this section reflect requirements that were found throughout the earlier document but consolidated in the 2018 version.
Revision
The 2015 version included a section titled Establishing Data Criticality and Inherent Integrity Risk that is substantially expanded with new text and detail. Additional detail is provided in examples.
Revision
Section 5.0, titled Designing Systems and Processes in the 2018 version, has also been substantially expanded. It addresses a GLP example where scribes record activities, such as for necropsies.
Revision
The format is revised from a tabulation format that included terms, definitions, and expectations/guidance (where relevant) in 2015 to a non-tabulated narrative format in 2018.
Definitions And Interpretations
Deletion
The revised definition of raw data in section 6.2 does not include the potential for the use of “true copies.”
Deletion
The definition of lifecycle (section 6.6) has been revised and omits the previously specified duration of archival arrangements and retrievability of data for inspection.
Deletion
The concept of a primary record has been removed. This removes confusion and perhaps bad practices the 2015 version may have appeared to support.
Addition
The revised definition of raw data in section 6.2 now includes source data as defined in the ICH GCP guidance. It also provides additional detail on simple electronic instruments that may store electronic data, such as pH meters or balances. Guidance is provided on how firms should manage situations where electronic data is retained.
Addition
Section 6.5 on data governance now includes requirements to ensure this is included in quality agreements and that data is “directly accessible on request from national competent authorities.”
Addition
Section 6.7 on Recording and Collection of Data is new.
Addition
Section 6.8 on data transfer/migration is new. Data transfer processes should be validated. This section also addresses the requirements for use of electronic worksheets, which I interpret to be spreadsheets such as Excel.
Addition         
Section 6.9 on Data Processing is new and requires traceability of “user defined parameters and addresses expectations for activities such as re-integration of chromatography data to ensure it is not being “manipulated to achieve a more desirable result.”
Addition
The 2018 revision adds section 6.10 on Excluding Data. For data that is excluded, the justification for doing so should be documented, and all data should be retained and available for review. This section does not apply to GPvP, as this is covered by pharmacovigilance legislation.
Addition
The 2018 version adds section 6.14 addressing electronic signatures. It references the MHRA/HRA draft guidance on the use of electronic informed consent for the GCP area.
Addition
Section 6.20 on IT Suppliers and Service Providers is an important and welcome addition and addresses software as a service, platforms as a service, and infrastructure as a service.
Addition
The glossary adds new terms and their definitions including: eCRF, ECG, data quality, DIRA, data cleaning, directly accessible, and advanced electronic signatures.
Revision
The definition of data (section 6.1) has been revised to be more detailed than simply “information derived or obtained from raw data” and includes the “+” attributes of “ALCOA +,” though it does not use this term. Data is to be complete, consistent, enduring, and available in addition to meeting the ALCOA attributes.
Revision
The revised definition of data integrity (section 6.4) includes the requirement to incorporate risk management: “quality and risk management systems including adherence to sound scientific principles and good documentation practices.” The definition is substantially expanded from the one-sentence version in the 2015 draft guidance.
Revision
The section on original record/true copy is now divided into two sections (6.11.1, titled “Original Record,” and 6.11.2, titled “True Copy”).
Original Record: This section is revised to address GCP examples, such as medical imaging results. It also is expanded to include examples where manual observations such as manual titrations and visual interpretations may need to be supported by second person verification.
True Copy: This section has been revised to state that true copies may be stored in a different electronic format than the original under specific circumstances. This section also states that when relying on “true copies,” the firm should consider risks that may be associated with the destruction of the original records. It also provides specific information on what should be verified to ensure a “true copy” includes adequate content. The new version also addresses how to accommodate situations where computer systems are no longer supported.
Revision
The section on Computerised System Transactions (section 6.12) now specifies that the time interval before saving data should be minimized for situations where multiple operations are combined into a single transaction. A paragraph is now included that addresses factors in this area that should be considered during system design.
The two figures in the 2015 version are not included in the 2018 document. For those who aren’t IT experts, the figures provided added value.
Revision And Deletion
The definition of audit trail has been substantially expanded in section 6.13. Further, some of the explanation is expanded and states that when the system administrator amends or turns off the audit trail, that action should be recorded and retained.
The 2015 version states that systems should have audit trails and unique login capability by the end of 2017. The 2018 version removes a specific date for meeting this requirement but does not remove the requirement.
The 2018 version states: “Where relevant audit trail functionality does not exist (e.g. within legacy systems) an alternative control may be achieved for example defining the process in an SOP and use of log books. Alternative controls should be proven effective.
Where add-on software or a compliant system does not currently exist, continued use of the legacy system may be justified by documented evidence that a compliant solution is being sought and that mitigation measures temporarily support the continued use.1
1 It is expected that GMP facilities with industrial automation and control equipment/systems such as programmable logic controllers should be able to demonstrate working towards system upgrades with individual login and audit trails (reference: Article 23 of Directive 2001/83/EC).”
The 2018 version addresses audit trail review and states that these may be reviewed as a list of relevant data or by an exception reporting process. This guidance defines the content of an exception report and states it is a “validated search tool.” Further, reviewers must have “sufficient knowledge and system access to review relevant audit trails, raw data and meta data.”
MHRA also states they may identify a deficiency when systems that do not meet audit trail or individual user account expectations do not have remediation identified or subsequently implemented.
Revision
Data Review and Approval, described in section 6.15, is expanded. The revision states, “Data review should be documented and the record should include a positive statement regarding whether issues were found or not, the date that review was performed and the signature of the reviewer.” As part of gap assessments, firms should consider how they address the requirement for a “positive statement” regarding the data review.
This section also addresses features of data review when a different organization generated the data, e.g., contract laboratories or contract manufacturers. In my opinion, this is an important addition.
Revision
Section 6.16 addressing computerized system user access/system administrator roles is revised to 1) address login at the operating system and application levels, 2) address MRP systems that may have non-GXP components, and 3) revise access rights depending on clinical trial status for GCP documentation.
Revision
Section 6.17 on Data Retention adds the term “validated” to describe the scanning process for paper records. The 2018 version does not address the circumstances where data is retained by a third party.
Revision
Sections 6.17.1 and 6.17.2 on archive and backup, respectively, have been substantially expanded. The archive section specifically addresses how to manage legacy systems.
Revision
Section 6.18 on file structure has been simplified and shortened. Details of flat files versus relational database structure have been eliminated.






回复

使用道具 举报

发表于 2018-3-24 21:28:57 来自手机 | 显示全部楼层
感谢楼主。

回复

使用道具 举报

药徒
发表于 2018-3-28 09:04:48 | 显示全部楼层
谢谢分享,好好学习下
回复

使用道具 举报

发表于 2018-3-28 09:19:04 | 显示全部楼层
回复

使用道具 举报

药士
发表于 2018-5-22 18:17:02 | 显示全部楼层
补充一下(与2015版的部分区别):
Comparing the March 2018 and the March 2015 guidances, the following defined terminologies were included in the March 2018 guidance, but were not covered in the March 2015 guidance: (1) recording and collecting data, (2) data transfer/migration, (3) data processing, (4) electronic signature, (5) data approval, and (6) IT suppliers and service providers.  It was noted that the “primary record” in the March 2015 guidance was incorporated into the “raw data” definition in the March 2018 guidance.  Other differences include deletion of the terms “flat file” and “relational database” that were covered in the March 2015 guidance.
MHRA, March 2018 ‘GXP’ Data Integrity Guidance and Definitions
回复

使用道具 举报

发表于 2018-6-11 11:27:19 | 显示全部楼层
谢谢分享  好好学习
回复

使用道具 举报

药徒
发表于 2018-9-2 10:42:05 | 显示全部楼层
asima 发表于 2018-3-14 08:28
好东西 下了另外一个中英文版!

问下中英文版本下载地址方便给吗
回复

使用道具 举报

药徒
发表于 2018-9-3 09:04:27 | 显示全部楼层
回复

使用道具 举报

药徒
发表于 2018-10-26 14:05:20 | 显示全部楼层
谢谢,辛苦了
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( (京)-非经营性-2014-0058 京ICP证150354号 京ICP备14042168号-1 )

GMT+8, 2024-3-29 07:59

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表